Major Depressive Disorder

At the beginning of the COVID-19 pandemic, one in three new moms had postpartum depression, which was nearly three times higher than the rate before the pandemic, data published in BMC Research Notes showed.

Women who took antidepressant medication had persistent depressive and anxiety symptoms during pregnancy and postpartum, with some women experiencing increased anxiety symptoms, data showed.

Novamind Inc., a company specializing in psychedelic medicine, announced it will conduct a phase 2 clinical trial examining psilocybin for major depressive disorder.

A questionnaire effectively measured psychosocial functioning of patients with major depressive disorder, according to study results published in General Psychiatry.

AbbVie has submitted a supplemental new drug application for Vraylar to the FDA for the adjunctive treatment of major depressive disorder in patients receiving ongoing antidepressant therapy, according to a press release.

Agomelatine proved safe and effective in treating adolescents with major depressive disorder who received psychosocial counseling, according to a double-blind randomized controlled phase 3 trial published in Lancet Psychiatry.

Sunovion and Otsuka announced the first patient has been randomly assigned in their phase 3 clinical study of non-racemic amisulpride for treating major depressive episodes linked to bipolar I disorder.

As symptom severity for major depressive disorder and treatment-resistant depression increases, so do costs to health systems, according to a retrospective cohort study published in the Journal of Clinical Psychiatry.

Esmethadone produced fast and consistent positive outcomes in patients for whom previous treatments for depression were not effective, according to a randomized, double-blind study published in the American Journal of Psychiatry.

A pair of West Coast health firms have announced a partnership to launch a decentralized clinical study in precision psychiatry.